Pharma, biotech shares soar as Trump win calms pricing talk

Go back to Pharma, biotech shares soar as Trump win calms pricing talk

UBS Cuts Price Target as Centene (CNC) Shares Weaken Following 2016 Presidential Election

November 10, 2016 11:06 AM EST

UBS maintained a Buy rating on Centene (NYSE: CNC), and cut the price target to $73.00 (from $80.00), as shares weaken due to uncertainty following the 2016 election. CNC shares declined more than 19% on Wednesday. Based on previous public comments by Congressional leaders, such as House Speaker Paul Ryan, alternative coverage options need to be... More

Standpoint Research Downgrades Celgene (CELG) to Hold

November 9, 2016 11:34 AM EST

Standpoint Research downgraded Celgene (NASDAQ: CELG) from Buy to Hold.

For an analyst ratings summary and ratings history on Celgene click here. For more ratings news on Celgene click here.

Shares of Celgene closed at $108.45 yesterday.

... More